Infliximab for Injection
Efficacy and safety are equivalent to the original drug (Johnson & Johnson/Merck & Co.
The first infliximab biosimilar marketed in China
Infliximab for Injection (Reminton), a recombinant anti-TNF-alpha chimeric monoclonal antibody, was approved for marketing by the National Medical Products Administration (NMPA) on July 14, 2021. It is the first infliximab biosimilar marketed in China. Taking advantage of CHO cell expression system, Remin_x005f ton has been proved with good efficacy, better safety, and lower immunogenicity in clinical studies.
Indications:
Crohn's disease in adults and children over 6 years of age, stulizing Crohn's disease,
ulcerative colitis in adults, ankylosing spondylitis, rheumatoid arthritis, and psoriasis.
Recommended reading
Related products
-
Prune/Plum Powder Extract
Contact UsPlums are delicious and nutritious fruits that offer a variety of health benefits. They are rich in vitamins, minerals, antioxidants, and dietary fiber. Here are some of the key health benefits associ
-
Bulb Flat
Contact UsBulb Flat Steel is mainly used in shipbuilding, marine engineering, steel structure engineering, and bridge engineering.Most ships choose ball-flat steel for structural design.
-
FO-Curtain Series (P10.4,P12.5,P15.6,P25,P31.2)(500×1000mm)
Contact UsLED Curtain Display-P10.4, P12.5, P15.6, P25, P31.2
-
Recombinant Collagen Repair Mask
Contact UsCOLLAGEN SUPPLEMENTATION – A SCIENTIFIC SOLUTION TO AGING SKIN
Reviews
There are no reviews yet.